MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Randomized Trial comparing Directional DBS with Ring-mode DBS in PD

    V. Sisodia, TR. Ten Brinke, H. Jergas, VJJ. Odekerken, D. Verbaan, JM. Dijk, M. Bot, M. Beudel, P. Munckhof, MT. Barbe, PR. Schuurman, RMA. de Bie (Amsterdam, Netherlands)

    Objective: To evaluate whether directional DBS is more effective in reducing PD motor symptoms and causes fewer stimulation-induced adverse effects (AE) than ring-mode DBS. Background:…
  • 2025 International Congress

    A Phase 1b Study to Investigate Safety and Tolerability of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease

    K. Holmström, K. Jääskeläinen, N. Kulesskaya, J. Koskinen, R. Holmnäs, A. Vuolanto, A. Domanska, M. Engström, P. Vainio, M. Scheinin, C. Videbaek, A. Tornio, Z. Lovro, F. Scheperjans, J. Rinne, H. Huttunen (Espoo, Finland)

    Objective: To investigate safety and tolerability of repeated subcutaneous (s.c.) doses of HER-096 in subjects with Parkinson’s disease. Background: HER-096 is a retro-inverso isomerized peptide…
  • 2025 International Congress

    Quercetin Reduces mtDNA Release in PRKN-Deficient and Oxidatively Stressed SH-SY5Y Cells

    G. Agyeah, J. Ghelfi, L. Gallucci, K. Wasner, P. Antony, A. Rakovic, S. Pereira, A. Grünewald (Belval Esch-sur-Alzette, Luxembourg)

    Objective: This study investigates the role of Parkin deficiency in mitochondrial dysfunction and its contribution to mitochondrial DNA (mtDNA) release in Parkinson’s disease (PD). We…
  • 2025 International Congress

    Advancements in Microbiome Research: Total Microbial Load, Differential Absolute Abundance, and Correlations with Immune Transcriptomics

    B. Palushaj, M. Chakraborty, I. Porter, G. Reynolds, E. Brooks, Z. He, A. Bhatt, K. Poston (Palo Alto, USA)

    Objective: Quantify total microbial load in the gut microbiome of people with Parkinson’s disease (PD) and compare the absolute abundance of bacterial taxa between PD…
  • 2025 International Congress

    Natural compound Protects Dopaminergic Neurons by Targeting Oxidative Stress and Cell Death Pathways in Parkinson’s Disease

    S. Pandey, R. Singh (Lucknow, India)

    Objective: This study aims to evaluate the neuroprotective potential of a natural compound that protects dopaminergic neurons by targeting oxidative stress and cell death pathways…
  • 2025 International Congress

    Chronic kidney disease, proteinuria, and mortality risk in patients with Parkinson’s disease: A longitudinal study

    K. Baik, M. Park, M. Kang, YJ. Park, SJ. Chung, K. Oh, SH. Kang, S. Koh (Seoul, Republic of Korea)

    Objective: To investigate whether chronic kidney disease (CKD) and proteinuria are associated with mortality rates in patients with Parkinson's disease (PD), using data from a large…
  • 2025 International Congress

    Early Introduction of COMT Inhibitors at Low Levodopa Doses Improves Long-Term Motor Complications in Parkinson’s Disease: A sub-analysis of the REONPARK Study

    J. García-Caldentey, D. Vilas Roldán, L. López-Manzanares, H. Brigas, D. Martins, J. Reis, J. Blanco Ameijeiras, M. Rodríguez-de Miguel, I. Tegel Ayuela (Palma de Mallorca, Spain)

    Objective: This sub-analysis of the REONPARK study aims to identify predictive factors for the greater effectiveness of COMT inhibitors (COMTi) in alleviating motor complications in…
  • 2025 International Congress

    Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers

    M. Minar, I. Straka, Z. Andre, M. Grofik, J. Necpal, M. Rusinkova, V. Han, Z. Kosutzka (Bratislava, Slovakia)

    Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    Glucagon Like Peptide-1 (GLP-1) Receptor Agonists for Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis

    F. Alnajjar, A. Abunamoos, M. Mustafa, Y. Aljazi, K. Moghib, A. Rababah, M. Alghaniem (Amman, Jordan)

    Objective: To evaluate the efficacy and safety of GLP-1 receptor agonists in Parkinson's disease (PD) by adding new 2025 randomized controlled trial (RCT) data, and…
  • « Previous Page
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • 65
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley